Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-08-28
DOI
10.3389/fimmu.2017.01024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
- (2017) Andres Forero et al. INVESTIGATIONAL NEW DRUGS
- Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
- (2017) Jon Bjoern et al. Oncotarget
- Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
- (2017) Zong Sheng Guo et al. Frontiers in Immunology
- Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study
- (2017) José Mordoh et al. Frontiers in Immunology
- A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
- (2017) Melanie Mediavilla-Varela et al. NEOPLASIA
- Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
- (2016) Shin Foong Ngiow et al. CANCER RESEARCH
- The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
- (2016) T Yamazaki et al. CELL DEATH AND DIFFERENTIATION
- Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
- (2016) George A. Dominguez et al. CLINICAL CANCER RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
- (2016) J. Galon et al. Journal of Translational Medicine
- Microsatellite instability in melanoma
- (2016) Ondřej Kubeček et al. MELANOMA RESEARCH
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-regulatory T cells
- (2016) Mads Hald Andersen Seminars in Immunopathology
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
- (2016) A. H. Long et al. Cancer Immunology Research
- PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
- (2016) Joseph M. Obeid et al. OncoImmunology
- Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
- (2016) Rikke B. Holmgaard et al. EBioMedicine
- TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells
- (2015) Marianne Boes et al. CANCER LETTERS
- Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus ery
- (2015) K. Masek-Hammerman et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
- (2015) H. M. Kluger et al. CLINICAL CANCER RESEARCH
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- (2015) J. M. Taube et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Genetic Evolution of Melanoma from Precursor Lesions
- (2015) A. Hunter Shain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression
- (2015) Laura Pinton et al. Oncotarget
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
- (2015) Mariana Aris et al. Frontiers in Immunology
- Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
- (2015) Florencia Paula Madorsky Rowdo et al. Frontiers in Immunology
- Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma
- (2015) I Chevolet et al. OncoImmunology
- Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
- (2015) Kavitha Gowrishankar et al. PLoS One
- Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment
- (2014) C. Cekic et al. CANCER RESEARCH
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
- (2014) M. F. Sanmamed et al. CLINICAL CANCER RESEARCH
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
- (2014) Chiara Camisaschi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo
- (2014) Shweta Joshi et al. PLoS One
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
- (2013) Cristina Iclozan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
- (2013) S. R. Goding et al. JOURNAL OF IMMUNOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Characterization of CD8+T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
- (2013) Daphné Benteyn et al. Biomed Research International
- Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
- (2012) G. Pietra et al. CANCER RESEARCH
- Lessons from Cancer Immunoediting in Cutaneous Melanoma
- (2012) Mariana Aris et al. Clinical & Developmental Immunology
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
- (2012) Pia Kvistborg et al. OncoImmunology
- Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer
- (2011) T T Sahin et al. CANCER GENE THERAPY
- Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
- (2011) Jonathan R. Brody et al. CELL CYCLE
- The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment
- (2011) Jung-Mi Lee et al. INTERNATIONAL JOURNAL OF CANCER
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma
- (2011) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Interleukin-2: Evaluation of Routes of Administration and Current Delivery Systems in Cancer Therapy
- (2008) Mohamed A. Shaker et al. JOURNAL OF PHARMACEUTICAL SCIENCES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now